venlafaxine besylate monohydrate | 609345-59-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: venlafaxine besylate monohydrate
• 英文别名: benzenesulfonic acid;1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexan-1-ol;hydrate
• CAS: 609345-59-7
• 化学式: C₆H₆O₃S*C₁₇H₂₇NO₂*H₂O
• 分子量: 453.6
• InChiKey: XHPQSXIKZWZGIP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.14
• 重原子数：
  31
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  96.4
• 氢给体数：
  3
• 氢受体数：
  7

文献信息

• Venlafaxine besylate
  申请人：SYNTHON BV

  公开号：US20030195249A1

  公开（公告）日：2003-10-16

  Venlafaxine besylate compounds provide certain advantages over venlafaxine hydrochloride and are useful in forming pharmaceutical compositions and n treating venlafaxine-treatable diseases and conditions. Venlafaxine besylate can be easily formulated into an extended release dosage form including a hydrogel tablet as well as other matrix-based tablet compositions. A preferred tablet making process involves hot melt granulation.

  Venlafaxine besylate化合物相对于Venlafaxine hydrochloride具有一定优势，并且在制备药物组合物和治疗可用Venlafaxine的疾病和病情方面非常有用。Venlafaxine besylate可以轻松制备成为延长释放剂型，包括水凝胶片剂和其他基质片剂组合物。首选的片剂制备工艺包括热熔造粒。
• [EN] VENLAFAXINE BASE<br/>[FR] BASE DE VENLAFAXINE
  申请人：SYNTHON BV

  公开号：WO2003082806A1

  公开（公告）日：2003-10-09

  The invention relates to a crystalline racemic venlafaxine base wherein said venlafaxine is in particle form having an average particle size within the range of 0.5 to 200 microns or a bulk density of at least 0.4 mg/ml, or a particular XRD pattern, to a process for making solid racemic venlafaxine base, which comprises precipitating racemic venlafaxine base from a solution of venlafaxine to form crystalline racemic venlafaxine base; wherein said precipitation is carried out in accordance with at least one of the following conditions: (i) said solution contains a combination of solvents comprising at least one organic polar solvent and at least one contrasolvent selected from water, an aliphatic hydrocarbon and an alicyclic hydrocarbon; or (ii) a seeding crystal of venlafaxine base is present.

  本发明涉及一种晶体外消旋文拉法辛碱基，其中所述文拉法辛以粒子形式存在，其平均粒径在0.5至200微米范围内或其堆积密度至少为0.4毫克/毫升，或具有特定的XRD图案，以制备固体外消旋文拉法辛碱基的方法，包括从文拉法辛溶液中沉淀外消旋文拉法辛碱基以形成晶体外消旋文拉法辛碱基；其中所述沉淀是根据以下至少一种条件进行的：（i）所述溶液含有至少一种有机极性溶剂和至少一种对比溶剂，所述对比溶剂选自水，脂肪烃和萜烃；或（ii）存在文拉法辛碱基的种晶。
• Extended release venlafaxine besylate tablets
  申请人：Cucala Escoi Joan

  公开号：US20060018963A1

  公开（公告）日：2006-01-26

  Venlafaxine besylate is formulated into an extended release tablet in high loading rates by use of a coating that contains ammonio methacrylate copolymer(s).

  苯乙酸文拉法辛通过使用含有甲基丙烯酸铵共聚物的包衣，配制成高负载率的缓释片。
• VENLAFAXINE BESYLATE
  申请人：Synthon B.V.

  公开号：EP1485344A1

  公开（公告）日：2004-12-15
• Extended Release Pharmaceutical Formulation of Venlafaxine and Method of Manufacturing the Same
  申请人：Nagaraju Nagesh

  公开号：US20090175934A1

  公开（公告）日：2009-07-09

  Disclosed herein is an extended release pharmaceutical formulation suitable for once daily administration, comprising a highly water soluble core consisting essentially of about 30 to about 40% by weight of venlafaxine hydrochloride, about 50 to about 80% by weight of water soluble diluent and about 2 to about 10% of water soluble binder and a coating layer having an effective combination of rate controlling polymers comprising water-soluble polymer and water insoluble, water permeable polymer.